Phase 2 Trial of Parotid-sparing Intensity-modulated Radiotherapy in Head and Neck Cancer

Share this content:
Researchers are evaluating the effectiveness of parotid-sparing intensity-modulated radiotherapy for reducing xerostomia in head and neck cancer.
Researchers are evaluating the effectiveness of parotid-sparing intensity-modulated radiotherapy for reducing xerostomia in head and neck cancer.

Title: Phase II Study of Whole or Partial Parotid Sparing Intensity Modulated Radiotherapy in Patients With Head and Neck Cancers1

Principal Investigator: Christopher Nutting, PhD, MD, FRCR, MRCP, MB BS, Royal Marsden NHS Foundation Trust

Description: For this observational, phase 2 study (ClinicalTrials.gov Identifier: NCT02068313), researchers are evaluating the effectiveness of intensity-modulated radiotherapy for reducing xerostomia among patients with head and neck cancer, as well as determining the dose threshold for parotid glands.

The study's primary outcomes are xerostomia reduction and dose threshold for whole parotid glands and superficial lobes thereof. Secondary outcomes include toxicity, overall survival, disease-free survival, logo-regional control, and quality of life, all measured over 5 year periods.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02068313.

Status: This study is open and recruiting patients as of March 16, 2017.

This study is sponsored by the Royal Marsden NHS Foundation Trust.

Reference

  1. Clinicaltrials.gov. Phase II study of whole or partial parotid sparing intensity modulated radiotherapy in patients with head and neck cancers. NCT02068313. https://clinicaltrials.gov/ct2/show/NCT02068313. Accessed March 16, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters